Taikang CNI Public Health and Medical Health ETF

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

Hengrui Medicine and Braveheart Bio Report Positive Phase 2 Results for HRS/BHB-1893 in Treating nHCM

Hengrui Medicine Receives Approval for Two Drug Clinical Trials

Fosun Pharma Subsidiary Approved for Phase I Clinical Trial of HLX05-N for Metastatic Colorectal Cancer in the US

Hengrui Pharmaceutical Obtains Clinical Trial Approval Notifications for Multiple New Drugs

Fosun Pharmaceutical's Subsidiary's Venlafaxine Hydrochloride Extended-Release Tablets Approved for Registration

Huaren Pharmaceutical Receives Approval for Clinical Trials of HRS-3005

Hengrui Pharmaceutical Repurchased 12,056,200 A-shares in April

01666

00570

03613

159760

<p>Recently, the National Chinese Herbal Pieces Alliance Procurement Office released centralized procurement documents, proposing to purchase 41 varieties of Chinese herbal pieces, categorized into two specification grades: selected goods and unified goods. This procurement follows the principles of 'stabilizing clinical use, ensuring quality, opposing internal competition, and preventing bid rigging,' led by the Shandong Medical Security Bureau, and is expected to reshape a market valued at 300 billion yuan</p>

Wallstreetcn

TONG REN TANG

TRAD CHI MED

TONGRENTANGCM

CR Sanjiu

E Fund CSI HK Equities Medical and Health Integration ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Universal 800 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI All Share Health Care ETF

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

688336

160219

164401

<p>The Taikang CNI Public Health and Medical Health ETF rose over 1% at one point, with a transaction volume of 2.3563 million yuan. The Guotai Guozheng Health Care Sector Index fell by 0.21%. Component stocks showed mixed performance, with Sunshine Guojian Pharmaceutical leading the rise at 12.32%. At the 2026 European Lung Cancer Conference, several domestic pharmaceutical companies showcased cutting-edge technologies and released key clinical data. China International Capital Corporation is optimistic about the CXO sector, expecting double-digit revenue growth in 2026, and suggests seizing the opportunity for industry recovery</p>

腾讯新闻 - 财经

Sunshine Guojian Pharmaceutical

Guotai Guozheng Health Care Sector Index Fund-A

First Seafront CSI Health Industry Index Fund

Taikang CNI Public Health and Medical Health ETF rose over 1% during trading, showcasing domestic innovative achievements at an international event, and the CXO sector is experiencing a comprehensive recovery

Taikang CNI Public Health and Medical Health ETF(159760.SZ)

New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to Change

Taikang CNI Public Health and Medical Health ETF rose over 1% during trading, showcasing domestic innovative achievements at an international event, and the CXO sector is experiencing a comprehensive recovery